A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 267
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : GLP-1RAs
Long Form : glucagon-like peptide-1 receptor agonists
No. Year Title Co-occurring Abbreviation
2020 An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. T2DM
2020 An orally available hypoglycemic peptide based on caveolae transcytosis displays improved hypoglycemic effects and body weight control in db/db mice. OHP2
2020 An overview of GLP-1 agonists and recent cardiovascular outcomes trials. CVOTs, T2D
2020 Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications. CVD, oADMs, SGLT-2is, T2D
2020 Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study. eGFR, SOT
2020 Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. ---
2020 Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis. BP, SGLT2is
2020 Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis. BMI, CI, GRADE, NMA, RCTs, RoB, WC
2020 Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. CIs, OADs, RCTs, SMD
10  2020 Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis. SGLT-2is
11  2020 Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. PIONEER, T2D
12  2020 Emerging glucose-lowering therapies: a guide for cardiologists. SGLT2i, T2DM
13  2020 Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists. CVOTs, I/E, T2D
14  2020 Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. CV, CVOTs, HR, MACE, SGLT2is
15  2020 GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. CI, CVOTs, OR
16  2020 Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials. CIs, MACE, MH-ORs
17  2020 Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. MI
18  2020 Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials. CV, CVOTs
19  2020 Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning. DPP-4is, MI, SGLT-2is
20  2020 Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. FDA, HbA1c
21  2020 Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. CVD, PCSK9, SGLT2, T2DM
22  2020 Relation between improvement of glycemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: a meta-analysis with metaregression. CIs, CVOTs, HbA1c, MACE, T2D
23  2020 Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view. CVD, SGLT2is, T2DM
24  2020 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes. CVD
25  2020 Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study. ADD, CI, DPP-4i, HR, PY, SGLT-2i, T2DM
26  2020 Transitioning to non-insulin therapy in a patient receiving high dose insulin. ---
27  2020 Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. CV, DPP-4is, SGLT2-is
28  2020 Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study. DDD
29  2020 Weight-lowering effects of glucagon-like peptide-1 receptor agonists and detection of breast cancer among obese women with diabetes. CIs, HRs
30  2019 A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. DPP-4, SGLT2
31  2019 A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. ---
32  2019 A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. FM, LBM, SGLT2is
33  2019 ADDITION OF DULAGLUTIDE FOR A HIGH-DOSE INSULIN REQUIRING PATIENT WITH TYPE 2 DIABETES MELLITUS: A REMARKABLE RESPONSE. HbA1c, T2DM
34  2019 Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes. T1D
35  2019 Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms. AMPK
36  2019 Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials. CIs, CV, CVOTs, MACEs, RR
37  2019 Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. ---
38  2019 Body Weight Considerations in the Management of Type 2 Diabetes. T2D
39  2019 Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. SGLT2
40  2019 Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. DPP-4, HF, MACE, SGLT2
41  2019 Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists. H2RAs, PPIs
42  2019 Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. CV, SGLT-2is, T2D
43  2019 Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. T2DM
44  2019 Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden. CEA, CV, IHE, NMA, T2D
45  2019 Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. DBP, RCTs, SBP
46  2019 Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance. OGTT
47  2019 Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. ---
48  2019 Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. DKD, DPP, eGFR, ESRD, SGLT2is, T2DM
49  2019 Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! DPP-4i, NAFLD, NASH, SGLT2i, T2DM
50  2019 Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis. HbA1c, MET, SU, T2D
51  2019 Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. CrI, DPP-4i, MD, RCTs, SBP, SGLT2i, SLR
52  2019 GLP-1 receptor agonists and cardiovascular outcome trials: An update. CV, FDA, MACE
53  2019 GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. CIs, CVD, CVOTs, HRs, MACE, T2D
54  2019 GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective. ---
55  2019 Glucagon modulates proliferation and differentiation of human adipose precursors. ASCs, GCGR
56  2019 Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. T1DM
57  2019 Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. CI
58  2019 Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. CI, OR, T2DM
59  2019 Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. ADRs
60  2019 Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area. ---
61  2019 Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features. T2D
62  2019 Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. GRADE, RCTs, RR, RR, SGLT-2i, T2DM
63  2019 Improved Clinical Outcomes With Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs With or Without Insulin in Overweight Indian Patients With Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting. BMI, SD, T2DM, U-ACR, VLDL
64  2019 Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. ---
65  2019 Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits. ASCVD, CV, CVD, CVOTs, HF, MACE, MI, SGLT2
66  2019 Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. CI, DPP-4is, OR, ORs, T2DM
67  2019 Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. FRCs, IDegLira, iGlarLixi, T2D
68  2019 Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials. CI, EAIR
69  2019 Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment. CV, DCE, T2D
70  2019 Pharmacokinetic Study of SKL-18287, a Novel Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, in Rats, Monkeys and Mini-Pigs. ---
71  2019 Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. CV, CVOTs, SGLT, T2D
72  2019 Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. NICE, SGLT-2is
73  2019 Preventing and treating kidney disease in patients with type 2 diabetes. CKD, RAAS, SGLT2is
74  2019 Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. BP, CV, RCGP, RSC
75  2019 Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. DN, SGLT-2i
76  2019 SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins. 3P-MACE, ADD, CV, US
77  2019 Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus. ADA/EASD, DPP4, SGLT2
78  2019 Sodium-glucose co-transporter inhibitors: Medications that mimic fasting for cardiovascular prevention. CVD, SGLT2
79  2019 Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis. AEs, DPP-4, QOL
80  2019 The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. CI, FBG, MET, RCTs, SITA, T2DM, WMD
81  2019 The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. NAFLD, SGLT2
82  2019 The effects of incretin-based therapies on beta-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials. CI, DPP-4is, FPG, GRADE, HOMA-beta, RCTs, T2DM, WMD
83  2019 The future of new drugs for diabetes management. CV, CVOTs, DPP-4, SGLT2
84  2019 The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution. WAT
85  2019 The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States. ASCVD, SGLT-2is, T2DM
86  2019 The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia. OADs, T2D
87  2019 Treatment patterns, glycemic control and bodyweight with canagliflozin 300mg versus GLP1RAs in Type II diabetes patients. ---
88  2019 Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials. DPP-4i, HF, HR, RCTs, SGLT-2i, T2D
89  2019 Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. DKD, SGLT-2is, T2D
90  2019 What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes. SGLT2
91  2019 [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes]. SGLT2is
92  2019 [Effect of glucagon-like peptide 1 receptor agonists on body fat redistribution and muscle mass in overweight and obese type 2 diabetic patients]. BMI, VAI, WHR
93  2018 A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. T2D
94  2018 Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. T2DM
95  2018 Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review. T2D
96  2018 Battle of GLP-1 delivery technologies. Fc, FDA
97  2018 Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes. ---
98  2018 Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. CVOTs, MACEs, SGLT2is, T2DM
99  2018 Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. SGLT2is
100  2018 Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. ASCVD, ER, MACE, T2DM